Raymond James & Associates Cytokinetics Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Cytokinetics Inc stock. As of the latest transaction made, Raymond James & Associates holds 4,107 shares of CYTK stock, worth $200,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,107

Previous 3,873 6.04%

Holding current value

$200,709

Previous $209,000 3.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$51.22 - $60.16 $11,985 - $14,077	234 Added 6.04%	4,107 $216,000
Q2 2024 Jul 19, 2024	SELL	$47.86 - $75.05 $192,923 - $302,526	-4,031 Reduced 51.0%	3,873 $209,000
Q1 2024 Apr 22, 2024	SELL	$63.75 - $108.06 $441,341 - $748,099	-6,923 Reduced 46.69%	7,904 $554,000
Q4 2023 Jan 16, 2024	SELL	$26.88 - $83.49 $50,023 - $155,374	-1,861 Reduced 11.15%	14,827 $1.24 Million
Q3 2023 Oct 24, 2023	SELL	$29.46 - $36.61 $6,451 - $8,017	-219 Reduced 1.3%	16,688 $491,000
Q2 2023 Jul 25, 2023	SELL	$32.62 - $40.75 $16,701 - $20,864	-512 Reduced 2.94%	16,907 $551,000
Q1 2023 Apr 14, 2023	BUY	$33.36 - $45.71 $366 - $502	11 Added 0.06%	17,419 $612,000
Q4 2022 Feb 08, 2023	BUY	$35.77 - $51.11 $98,439 - $140,654	2,752 Added 18.78%	17,408 $797,000
Q3 2022 Oct 25, 2022	SELL	$38.54 - $54.52 $39,503 - $55,883	-1,025 Reduced 6.54%	14,656 $710,000
Q2 2022 Aug 12, 2022	BUY	$33.93 - $48.92 $12,214 - $17,611	360 Added 2.35%	15,681 $616,000
Q1 2022 May 11, 2022	BUY	$29.74 - $46.0 $455,646 - $704,766	15,321 New	15,321 $564,000
Q4 2020 Feb 12, 2021	SELL	$15.26 - $28.61 $149,303 - $279,920	-9,784 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$20.58 - $28.96 $201,354 - $283,344	9,784 New	9,784 $212,000

Others Institutions Holding CYTK

# of Institutions

409

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.6B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Cytokinetics Inc Transaction History